Results 291 to 300 of about 456,798 (336)

Immune Checkpoint Inhibitor-Related Hypophysitis and Pituitary Dysfunction: A Systematic Review of Diagnosis and Management. [PDF]

Cureus
SirDeshpande P, Hegde SBS, Akhtar H.
europepmc   +1 more source

Limited evidence of pseudoprogression following immune checkpoint inhibitor (ICI) therapy in glioblastoma. [PDF]

Neurooncol Adv
Rhee JY, Ospina Botero JP, Nelson T, Song KW, Parsons MW, Gerstner ER, Dietrich J.   +6 more
europepmc   +1 more source

Patient-Reported Symptom and Symptom Clusters During Immune Checkpoint Inhibitor Therapy for Cancer Patients: A Cross-Sectional Survey. [PDF]

Health Sci Rep
Ren S, Yang J, Xu H, Jin J, Wang S, Han B, Zhang W, Lv Y, Liu J.   +8 more
europepmc   +1 more source

Genomic and transcriptomic analyses of melanoma in Japanese patients reveal candidate biomarkers for immune checkpoint inhibitor responders. [PDF]

Commun Med (Lond)
Kimura T, Tanaka N, Maekawa T, Kiniwa Y, Okuyama R, Asai J, Matsushita S, Uchi H, Kato H, Nagase K, Kobayashi A, Tanemura A, Fujimura T, Fujisawa Y, Kunimoto K, Ito T, Mori S, Yoshino K, Yamazaki N, Yano H, Komohara Y, Noda T, Kiyotani K, Mori S, Fukushima S.   +24 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Microbiome alteration via fecal microbiota transplantation is effective for refractory immune checkpoint inhibitor–induced colitis

Science Translational Medicine, 2023
Immune checkpoint inhibitors (ICIs) target advanced malignancies with high efficacy but also predispose patients to immune-related adverse events like immune-mediated colitis (IMC).
Taylor M. Halsey, A. Thomas, Tomoyoshi Hayase, Weijie Ma, Hamzah Abu-Sbeih, Baohua Sun, E. Parra, Zhi-Dong Jiang, H. Dupont, Christopher A. Sanchez, Rawan K. El-Himri, Alexandria Brown, Ivonne I. Flores, Lauren A. L. McDaniel, Miriam R. Ortega Turrubiates, Matthew Hensel, D. Pham, S. Watowich, Eiko Hayase, Chia-Chi Chang, R. Jenq, Yinghong Wang   +21 more
semanticscholar   +1 more source

Immune Checkpoint Inhibitor Toxicity

Current Oncology Reports, 2018
Immune checkpoint inhibitors have revolutionised the treatment of multiple malignancies and have a growing list of indications. As our familiarity with these agents grows, so does our understanding of their unique spectrum of toxicities. Here, we will review the literature regarding the toxicities of checkpoint inhibitors and address challenges ...
David J, Palmieri, Matteo S, Carlino
openaire   +2 more sources

Immune checkpoint inhibitor myocarditis

Current Opinion in Cardiology, 2019
The purpose of this study is to summarize and highlight the recent literature regarding immune checkpoint inhibitor myocarditis.The use of immune checkpoint inhibitors, a promising form of immunotherapy, is rapidly increasing in oncology. These drugs have been recently found to cause a fulminant myocarditis associated with a high-case fatality rate ...
Jayant, Raikhelkar, Nir, Uriel
openaire   +2 more sources

Mechanisms of Resistance to Immune Checkpoint Blockade: Why Does Checkpoint Inhibitor Immunotherapy Not Work for All Patients?

American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting, 2019
The emergence of immune checkpoint blockade therapies over the last decade has transformed cancer treatment in a wide range of tumor types. Unprecedented and durable clinical responses in difficult-to-treat cancer histologies have been observed. However,
C. Fares, E. V. Van Allen, C. Drake, J. Allison, S. Hu-Lieskovan   +4 more
semanticscholar   +1 more source